Research programme: interferon-alpha biosynthesis stimulants - 3M PharmaceuticalsAlternative Names: Interferon-alpha biosynthesis stimulants research programme - 3M Pharmaceuticals
Latest Information Update: 22 Apr 2003
At a glance
- Originator 3M Pharmaceuticals
- Mechanism of Action Interferon alpha stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Viral infections
Most Recent Events
- 02 May 2001 Preclinical development for Viral infections in USA (Unknown route)